} .s7FB0030E { width:111.07pt; display:inline-block } .s9852CA4C { width:7.54pt; display:inline-block } .s9E436411 { width:138.09pt; display:inline-block } .s4ACA9207 { page-break-before:always; clear

} .sC60B69EF { width:127.74pt; display:inline-block } .s9852CA4C { width:7.54pt; display:inline-block } .s9E436411 { width:138.09pt; display:inline-block } .s4ACA9207 { page-break-before:always; clear

} .s7FB0030E { width:111.07pt; display:inline-block } .s9852CA4C { width:7.54pt; display:inline-block } .s9E436411 { width:138.09pt; display:inline-block } .s4ACA9207 { page-break-before:always; clear

Vu la procédure suivante : Par une requête et des mémoires enregistrés le 23 décembre 2022, le 26 avril et le 12 juillet 2024, la société Life Scientific Limited, représentée par Me Bloch-Moreau, demande

} .s6163AF01 { width:168.94pt; display:inline-block } .s5B081A9D { width:168.28pt; display:inline-block }     FIFTH SECTION DECISION Application no. 24705/14 Adem KESKIN and Others against Germany

New Roman'; display:inline-block } .s9CB9BE2 { margin-top:14pt; margin-left:51.05pt; margin-bottom:6pt; text-indent:-17.05pt; text-align:justify; page-break-inside:avoid; page-break-after:avoid; line-height

} .s7FB0030E { width:111.07pt; display:inline-block } .s9852CA4C { width:7.54pt; display:inline-block } .s9E436411 { width:138.09pt; display:inline-block } .s4ACA9207 { page-break-before:always; clear

} .s7FB0030E { width:111.07pt; display:inline-block } .s9852CA4C { width:7.54pt; display:inline-block } .s9E436411 { width:138.09pt; display:inline-block } .s4ACA9207 { page-break-before:always; clear

} .s7FB0030E { width:111.07pt; display:inline-block } .s9852CA4C { width:7.54pt; display:inline-block } .s9E436411 { width:138.09pt; display:inline-block } .s4ACA9207 { page-break-before:always; clear

} .s7FB0030E { width:111.07pt; display:inline-block } .s9852CA4C { width:7.54pt; display:inline-block } .s9E436411 { width:138.09pt; display:inline-block } .s4ACA9207 { page-break-before:always; clear

} .s7FB0030E { width:111.07pt; display:inline-block } .s9852CA4C { width:7.54pt; display:inline-block } .s9E436411 { width:138.09pt; display:inline-block } .s4ACA9207 { page-break-before:always; clear

} .sF435E5EF { width:171.27pt; display:inline-block } .s5B081A9D { width:168.28pt; display:inline-block }     FIFTH SECTION DECISION Application no. 69361/12 Stoyan Yordanov NEDELCHEV against

} .s7E088005 { width:177.86pt; display:inline-block } .sC30055DD { width:0.44pt; display:inline-block } .s2F7F4368 { width:167.84pt; display:inline-block }     FIFTH SECTION DECISION Application

} .s7FB0030E { width:111.07pt; display:inline-block } .s9852CA4C { width:7.54pt; display:inline-block } .s9E436411 { width:138.09pt; display:inline-block } .s4ACA9207 { page-break-before:always; clear

Accordingly, this part of the applications should be struck out of the list. B.

} .s8C2BF086 { width:220.78pt; display:inline-block } .s7602FED2 { width:18.21pt; display:inline-block } .sC1AC44A4 { width:228.11pt; display:inline-block } FOURTH SECTION DECISION Application no. 10621

} .sC986E16F { font-family:Arial; color:#ffffff } .sC5599237 { width:142.72pt; display:inline-block } .sC646A315 { width:14.54pt; display:inline-block } .s7FB0030E { width:111.07pt; display:inline-block

} .sBB23AF50 { width:178.62pt; display:inline-block } .s8EFC8F8 { width:32.36pt; display:inline-block } .s5A070004 { width:213.96pt; display:inline-block } .s32563E28 { margin-top:0pt; margin-bottom:0pt

} .sC646A315 { width:14.54pt; display:inline-block } .s8D17D8A5 { width:127.42pt; display:inline-block } .s9852CA4C { width:7.54pt; display:inline-block } .s9E436411 { width:138.09pt; display:inline-block

, to Ms Anna Marasca 2 000 000 Italian lire, and to each of the four heirs of Mr Ezio Marasca, Messrs.